New US Food and Drug Administration (FDA) guidance on laparoscopic uterine power morcellation in hysterectomy and myomectomy (November 2014).
The US FDA has changed its guidance to warn against the use of laparoscopic power morcellators in the majority of women undergoing myomectomy or hysterectomy for treatment of fibroids. The FDA believes that the risk of spreading unsuspected uterine sarcoma within the abdomen and pelvis is higher than previously thought.
Because of this risk and the availability of alternative surgical options for most women, the FDA has strengthened its guidance to recommend that alternative treatment options should be considered for the removal of fibroids.
Sarcoma UK has submitted joint evidence with the British Sarcoma Group to a NICE consultation on hysteroscopic morcellation of uterine fibroids (November 2014).
Click for our morcellation_briefing23oct.pdf